Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

Core Viewpoint - Neuronetics, Inc. reported strong preliminary unaudited financial results for Q4 and full-year 2025, highlighting significant revenue growth and positive operating cash flow, indicating robust commercial execution and demand for its NeuroStar systems [2][3][10]. Financial Results Summary Fourth Quarter 2025 - Revenue for Q4 2025 was $41.8 million, representing a 23% increase on an adjusted pro-forma basis and an 86% increase compared to Q4 2024 on an as-reported basis [5][10]. - NeuroStar revenue for Q4 2025 was $18.3 million, up 9% on a pro-forma basis compared to the same period in 2024, with 49 NeuroStar Advanced Therapy systems shipped [5][10]. - Clinic revenue for Q4 2025 was $23.5 million, reflecting a 37% increase on an adjusted pro-forma basis compared to Q4 2024 [6][10]. - The company achieved positive operating cash flow of $0.9 million during Q4 2025 [6][10]. Full Year 2025 - Full-year revenue for 2025 was $149.2 million, a 15% increase on an adjusted pro-forma basis and a 99% increase compared to full-year 2024 on an as-reported basis [7][10]. - NeuroStar revenue for the full year 2025 was $62.2 million, up 0.9% on a pro-forma basis compared to 2024 [7][10]. - Clinic revenue for the full year 2025 was $87.0 million, a 28% increase on an adjusted pro-forma basis compared to 2024 [8][10]. - The company ended 2025 with total cash of $34.1 million, including cash, cash equivalents, and restricted cash [8][10].